Resources and Updates
Blog
The Coalition of endorsing organizations is working in partnership to provide updates of what is happening with the litigation, related legislation, and state and local implementation strategies.
States and local jurisdictions are poised to receive more funds to help with opioid abatement as a result of a recent court decision in the Purdue Pharma bankruptcy.
Starting people with opioid use disorder on buprenorphine is one of the evidence-based strategies to reduce overdose deaths. What do new research studies tell us about how well we’re doing and where we need to be putting additional resources?
To take advantage full advantage of the opioid litigation dollars, state and communities need to invest in recovery services and implement social justice reforms.
Numerous organizations have endorsed the provisions of methadone, buprenorphine and naltrexone by jails and prisons. A new study examines whether, in addition to saving lives, this approach is also cost-effective.
Starting people on buprenorphine in the emergency department after they’ve had an overdose has been proven to save lives. Practice change is hard, though. A recent article evaluated what happened after one program in Pennsylvania tried to do just that.
Some pharmaceutical companies and distributors have offered medications to treat opioid use disorder and overdose reversal drugs as part of the opioid settlements with states, cities, and counties. What should jurisdictions consider before entering these agreements so they can take full advantage of them?
How does the MDL align with the Principles?
Breaking down the proposed Multi-District Litigation settlement agreement, to see how it aligns with The Principles.
External Link
Visit the Opioid Settlement Tracker
For more in-depth information on the status of the opioid settlements and spending plans to explore how funds from the opioid litigations are being used to support public health response, visit The Opioid Settlement Tracker.